Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 10% – Should You Buy?

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) shot up 10% during mid-day trading on Monday. The company traded as high as $4.51 and last traded at $4.5310. Approximately 14,294,243 shares were traded during mid-day trading, a decline of 22% from the average daily volume of 18,334,430 shares. The stock had previously closed at $4.12.

Analyst Ratings Changes

Several research firms have weighed in on RXRX. Morgan Stanley set a $5.30 price target on Recursion Pharmaceuticals in a research report on Monday, August 17th. Wall Street Zen raised Recursion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 29th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Friday, July 17th. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Recursion Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $8.06.

Recursion Pharmaceuticals Price Performance

The company has a market capitalization of $2.48 billion, a price-to-earnings ratio of -4.45 and a beta of 1.04. The company has a quick ratio of 5.03, a current ratio of 5.03 and a debt-to-equity ratio of 0.01. The company has a 50 day simple moving average of $3.50 and a 200 day simple moving average of $3.37.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.01). The firm had revenue of $7.67 million during the quarter, compared to analyst estimates of $10.97 million. Recursion Pharmaceuticals had a negative net margin of 945.94% and a negative return on equity of 50.41%. During the same period in the prior year, the firm earned ($0.41) earnings per share. As a group, research analysts predict that Recursion Pharmaceuticals, Inc. will post -0.94 EPS for the current year.

Insider Buying and Selling at Recursion Pharmaceuticals

In related news, CEO Najat Khan sold 22,408 shares of the stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $3.52, for a total value of $78,876.16. Following the completion of the sale, the chief executive officer directly owned 2,072,890 shares in the company, valued at approximately $7,296,572.80. This represents a 1.07% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Blake Borgeson sold 30,000 shares of the business’s stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $3.34, for a total value of $100,200.00. Following the transaction, the director owned 6,158,287 shares in the company, valued at approximately $20,568,678.58. This represents a 0.48% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 82,408 shares of company stock worth $276,576 in the last 90 days. Company insiders own 6.65% of the company’s stock.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. MCF Advisors LLC acquired a new stake in Recursion Pharmaceuticals during the second quarter worth about $27,000. Fund Advisors of America Inc FL acquired a new stake in Recursion Pharmaceuticals during the second quarter valued at approximately $45,000. Integral Investment Advisors Inc. acquired a new stake in shares of Recursion Pharmaceuticals during the 1st quarter valued at $39,000. MQS Management LLC acquired a new position in shares of Recursion Pharmaceuticals in the 1st quarter valued at $41,000. Finally, Sequoia Financial Advisors LLC increased its position in shares of Recursion Pharmaceuticals by 51.5% in the first quarter. Sequoia Financial Advisors LLC now owns 15,162 shares of the company’s stock worth $47,000 after acquiring an additional 5,156 shares in the last quarter. Institutional investors and hedge funds own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc is a clinical-stage biotechnology company that uses biology, chemistry, automation and machine learning to discover and develop new medicines. The company’s technology platform is designed to generate and analyze large volumes of biological and chemical data, helping researchers identify potential drug candidates and better understand disease mechanisms.

Recursion has focused its research and development activities on areas including oncology, rare diseases and neuroscience.